Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

Medical Conditions

Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Sclerosis


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Nov 2022 Oct 2024

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : 300 mg of dazucorilant will be administered once daily in 4 softgel capsules of 75 mg dazucorilant/capsule.

Intervention Arm Group : CORT113176 (Dazucorilant) 300 mg;

Intervention Type : DRUG
Intervention Description : Dazucorilant and placebo will be administered once daily in 4 softgel capsules, 2 capsules with 75 mg dazucorilant/capsule and 2 capsules of placebo equivalent.

Intervention Arm Group : CORT113176 (Dazucorilant) 150 mg;

Intervention Type : OTHER
Intervention Description : Placebo will be administered once daily in 4 softgel capsules of placebo equivalent.

Intervention Arm Group : Placebo (matched to study drug);



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • 263
    Stoke on Trent
    ST4 6QG


The study is sponsored by Corcept Therapeutics





We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT05407324
Last updated 16 June 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.